Contents

Editorial
717 Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?
R Landewé, D van der Heijde

Viewpoint
719 Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment
C S Cowson, S E Cabral

Recommendation
722 European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects

Review
727 Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes
A Hsu, P Mossur

Clinical and epidemiological research
733 Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
D Alstaha, J Funovits, J Smolen
740 Validation of a numerical rating scale to assess functional impairment in hip and knee osteoarthritis: comparison with the WOMAC function scale
P Ornetti, M Dougados, S Paternotte, I Logeart, L Gossee
747 A multicentric, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
P Quartier, F Allantaz, R Gimaz, P Pilliet, C Messiaen, C Bardin, X Bossuyt, A Boutten, J Bienvenu, A Duquesne, O Richter, D Chausseabel, A Mogent, J Ranchereau, J F Al Janayed, P Landon, L Fascicul
755 Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase Ilib real-life study (TAMARA)
G R Barmste, E Feist, H Kelleer, J Braun, C Kleng-Korner, A Rubbert-Roth
760 Lupus Atherosclerosis Prevention Study (LAPS)
M A Pen, A N Kna, W Post, L Christopher-Stine, L S Mägde
766 Cardiac dysfunction in juvenile dermatomyositis: a case-control study
T Schwarz, H Suner, T Husebye, B Flate, I Sjaastad
772 Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase
M G H van de Sande, M J H de Haar, C van der Leij, P L Klarenbeek, W H Bos, M D Smith, M Aan, N de Vries, D van Schaardenburg, B A C Dijk, D M Gorler, P P Tzak
778 Roloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blind placebo-controlled trial
C C Moer, K Y Yang, C H To, L Yin Ho, K L Yu, H K Lee, K M Ma
785 High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
K Au, G Reid, J R Curry, M A Kremers, J D Greenberg, V Strand, D E Furstone, on behalf of the CORRONA Investigators
792 Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments
B Saleem, A K Brown, H Keen, S Nizam, J Freeston, R Weidefeld, Z Karm, M Quinn, E Hensor, P G Canaglia, P Emery
799 Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)
M Dougados, J Braun, S Smants, B Combe, M Efzat, P Celz, G Thabat, V Leblanc, I Logeart
805 Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study
A Currerain, F W Becker, D Hayashi, M D Cerna, J Niou, Y Zhang, M D Martin, A Kaur, J A Lynch, G C El-Khoury, K Batcher, I B Hughes, C M Neman, D T Felson
812 Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study
S A Provaz, A G Semly, J Hodaia, E Striander, S Agerwall, H Dagfju, K Angel, D Aaer, T K Kvien
818 The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel

Editor
Tore K Kvien
Associate Editors
Francis Berenbaum
Hans Björn
Dimitrios Bournas
Gerd Burmester
Mary Crow
Iain MacIntosh

The Eular Journal
Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd.
BMA House
Tavistock Square
London WC1H 9JR, UK

Impact Factor: 8.11

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD adheres to guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice produced by the Committee on Publication Ethics.

Copyright: © 2011 BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd, Tavistock Square, London WC1H 9JR, UK.

Volume 70 Issue 5 May 2011

MORE CONTENTS ➤

http://ard.bmj.com/info/unlocked.dtl

This article has been chosen by the editor to be of special interest or importance and is freely available online.

Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See http://ard.bmj.com/info/unlocked.dtl

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.

www.publicationethics.org.uk

When you have finished reading this please recycle it.
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program

Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis

HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus

Role of oxidative stress in rheumatoid arthritis: insights from the Nr2f1 knockout mice

The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype

Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis

Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study

Expansion of myelin autoreactive CD8+ T lymphocytes in patients with neuropsychiatric systemic lupus erythematosus

Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies

Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis

Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis

Expansion of myelin autoreactive CD8+ T lymphocytes in patients with neuropsychiatric systemic lupus erythematosus

Letters

The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance

Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis

Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis

Miscellaneous

Corrections